COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2019-03, Vol.33 (3), p.805-808
Hauptverfasser:	Klupsch, Kristina, Baeriswyl, Vanessa, Scholz, Roland, Dannenberg, Joana, Santimaria, Roger, Senn, David, Kage, Elena, Zumsteg, Adrian, Attinger-Toller, Isabella, von der Bey, Ulrike, König-Friedrich, Susann, Dupuy, Fanny, Lembke, Wibke, Albani, Clara, Wendelspiess, Severin, Dinkel, Lucijana, Saro, Dorina, Hepler, Robert W., Laszlo, George S., Gudgeon, Chelsea J., Bertschinger, Julian, Brack, Simon, Walter, Roland B.
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/1 13/2 631/67/1059/2325 631/67/1990/283/1897 82 Acute myelocytic leukemia Acute myeloid leukemia Analysis Animals Antibodies, Bispecific - pharmacokinetics Antibodies, Bispecific - pharmacology Binding proteins Brief Communication Cancer Research Cancer treatment CD3 antigen CD3 Complex - metabolism Cell Line, Tumor CHO Cells Cricetulus Critical Care Medicine Dosage and administration Drug therapy Female Gemtuzumab ozogamicin Hematology HL-60 Cells Humans Immunoglobulin G Immunoglobulin G - metabolism Intensive Internal Medicine Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - metabolism Medicine Medicine & Public Health Mice Mice, Inbred C57BL Mice, Inbred NOD Mice, SCID Myeloid leukemia Oncology Pharmacokinetics Pharmacology Sialic Acid Binding Ig-like Lectin 3 - metabolism Treatment outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!